‘Aarambh': CTSC installation ceremony and IEEE branch launch at YCCE
2
3
4
Nagpur: Department of computer technology at Yeshwantrao Chavan College of Engineering (YCCE) conducted 'Aarambh', the installation and oath-taking ceremony of the Computer Technology Students' Council (CTSC), in collaboration with the ACM Student Chapter.
The event also marked the official launch of the IEEE computer society student branch, a significant step toward enhancing the department's professional and academic outreach.
The ceremony was graced by Dr Prabhat Kumar Sharma of VNIT, Dr Kavita Singh (HoD, CT), Prof Shweta Gode, and Prof Kalyani Karule. Appointment letters and badges were presented to the newly selected council members, followed by the oath-taking ceremony for both the core and semi-core teams.
In his keynote address, Dr Sharma motivated students to lead with clarity, discipline, and innovation, encouraging them to embrace responsibility and pursue excellence. A key highlight of the event was the teaser release of CompuFest 2k25, the department's highly anticipated annual technical festival, which generated enthusiasm among the audience. Principal Dr UP Waghe guided in making the event a success.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
5 days ago
- Time of India
‘Aarambh': CTSC installation ceremony and IEEE branch launch at YCCE
1 2 3 4 Nagpur: Department of computer technology at Yeshwantrao Chavan College of Engineering (YCCE) conducted 'Aarambh', the installation and oath-taking ceremony of the Computer Technology Students' Council (CTSC), in collaboration with the ACM Student Chapter. The event also marked the official launch of the IEEE computer society student branch, a significant step toward enhancing the department's professional and academic outreach. The ceremony was graced by Dr Prabhat Kumar Sharma of VNIT, Dr Kavita Singh (HoD, CT), Prof Shweta Gode, and Prof Kalyani Karule. Appointment letters and badges were presented to the newly selected council members, followed by the oath-taking ceremony for both the core and semi-core teams. In his keynote address, Dr Sharma motivated students to lead with clarity, discipline, and innovation, encouraging them to embrace responsibility and pursue excellence. A key highlight of the event was the teaser release of CompuFest 2k25, the department's highly anticipated annual technical festival, which generated enthusiasm among the audience. Principal Dr UP Waghe guided in making the event a success.
Time of India
12-07-2025
- Time of India
YCCE's Team Titans advance to final round of ISRO Robotics Challenge 2025
Nagpur: Team Titans from Yeshwantrao Chavan College of Engineering (YCCE) has been selected for the final round of the prestigious ISRO Robotics Challenge (IRoC-U 2025), organized by UR Rao Satellite Centre. Tired of too many ads? go ad free now Competing against 23 other teams from across the country, the Titans have demonstrated exceptional expertise in robotics and engineering. The competition, which attracted 1,600 teams from institutions such as IITs, IIITs, NITs, and other esteemed colleges, began with a rigorous selection process. Initially, 177 teams were chosen based on their proposals. This was followed by two rounds: The qualification and elimination, where teams showcased their Autonomous Navigation Aerial Vehicle's readiness and capabilities. Recently, the competition's elimination round tested the Autonomous Navigation Aerial Vehicle in real-time via live video calls along with one ISRO scientist on-site to evaluate the performance. Team Titans excelled in this stage, earning their place among the top 16 finalists. The final round will take place at UR Rao Satellite Centre, Bengaluru, where the aerial vehicles will tackle tasks on an arena designed to simulate the Mars' surface. Team Titans is eager and prepared to compete with their aerial vehicle.
The Hindu
13-06-2025
- The Hindu
SII, DNDi partner for expanding human trials for dengue treatment
The Pune-based Serum Institute of India (SII) has partnered with Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organisation, to accelerate the clinical development of a monoclonal antibody (mab) treatment for dengue that will be affordable and accessible in low- and middle-income countries (LMICs). Mab are lab-produced antibodies, meant to mimic the ones naturally produced within the body to neutralise infectious agents, for instance viral particles. SII has already conducted pre-clinical studies and Phase I and II clinical trials of a potential candidate drug for dengue. This January, an expert committee of India's Central Drugs Standards Control Organisation (CDSCO) recommended that SII submit safety and efficacy data regarding the mab in a larger number of patients from phase III studies before recommending manufacturing and marketing approval for its dengue drug for adults. 'Through this collaboration, both SII and DNDi will develop a work plan to implement R&D, additional Phase III clinical trials along with a joint strategy to raise necessary funds and resources. Additionally, a joint project team will be formed to advance clinical trials, with the goal of registering and deploying the dengue monoclonal antibody in India and other dengue-endemic countries, provided the studies confirm its safety and efficacy,' a statement from DNDi noted. Testing in Brazil This could mean testing the treatment in Brazil and selected countries in south-east Asia. 'This collaboration with DNDi will be instrumental in advancing clinical development of a dengue monoclonal antibody in Brazil and potentially other endemic countries in Southeast Asia, with a focus on making treatment affordable and accessible,' Dr. Prasad Kulkarni, Executive Director, SII, said in a statement. 'We look forward to the positive impact this effort will have in reducing the burden of dengue and saving lives in vulnerable communities,' he said. 'India reports tens of thousands of dengue cases every year, with outbreaks occurring every two to three years in different states,' Dr. Kavita Singh, Asia Continental Lead & Director South Asia, DNDi, said in a statement. 'What is deeply concerning is that dengue is no longer confined to historically endemic regions but is rapidly expanding into newer states. Addressing this growing threat demands a multi-pronged approach, including strengthened vector control, surveillance, community awareness and, critically, the development of effective treatments and diagnostics,' she said. Dengue poses a significant threat, with 3.9 billion people at risk and cases more than doubling each year since 2021. It is also spreading to non-endemic areas due to climate change and urbanisation. Despite its prevalence and severity, there is still no specific treatment available for dengue. Medicines that could prevent mild cases from becoming severe would therefore play an important role in reducing mortality and preventing hospitals from being overwhelmed during outbreaks.
